In a breakthrough discovery that changes how we understand T cells and with implications of how we can better engineer custom immune responses to fight disease, Institute for Systems Biology researchers showed that the different disease-fighting functions of different T cells are determined by the genetically encoded T-cell receptor sequence that are unique to those cells.
Scientists for the first time have used CRISPR to substitute a gene to treat patients with cancer. The remarkable findings were published in the journal Nature and presented at the Society for Immunotherapy of Cancer (SITC) 2022.
Members of ISB’s Heath Lab and their collaborators have developed a way to sensitively detect and analyze neoantigen-specific T-cell populations from tumors and blood. This promising development may have implications for creating targeted, individual-specific cancer vaccines.
